Autonomix Medical (AMIX) Investor presentation summary

Technology overview

• Proprietary transvascular technology enables real-time, high-resolution neural signal detection and targeted nerve ablation for neurological diseases.

• Platform uses a custom ASIC-powered microchip and antenna array for precise neural mapping, ablation, and immediate verification of treatment effectiveness.

• User interface provides real-time neural signaling data with multi-channel, 360-degree positioning for directional targeting.

• Over 120 patents issued or pending, supporting a robust intellectual property portfolio.

Clinical results and studies

• Initial proof-of-concept (PoC 1) study in pancreatic cancer pain showed statistically significant, durable pain reduction and opioid elimination in responders.

• 100% of femoral access patients responded to treatment, with pain relief as early as 24 hours and sustained benefit at 3 months.

• Clinically meaningful pain reduction observed across all disease stages, including late-stage cancer patients.

• No device- or procedure-related serious adverse events reported.

• Ongoing PoC 2 study expands to additional visceral cancers and earlier stage pancreatic cancer.

Market opportunity and business strategy

• Targeting a combined $100 billion market opportunity across pain management, cardiovascular, and pulmonary indications.

• Initial focus on pancreatic cancer pain, with future expansion into chronic pain, digestive disorders, hypertension, and COPD.

• Revenue model includes capital equipment, disposable catheters, and annual software licenses.

• Path to FDA De Novo approval targeted for 2028, following U.S. IDE clinical trials.